Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Bevacizumab for patients with metastatic renal cancer: An update
James C. Yang
, Michael Gordon
, Michael Atkins
, Robert Motzer
, Allan Lipton
, Robert Flanigan
, Robert Figlin
, William Kaelin
, Daniel George
, W. Marston Linehan
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Research output
:
Contribution to journal
›
Article
›
peer-review
116
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Bevacizumab for patients with metastatic renal cancer: An update'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Bevacizumab
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Vascular Endothelial Growth Factor
60%
Disease Progression
40%
Toxic Effects
40%
Proteinuria
40%
Clear Cell Renal Cell Carcinoma (ccRCC)
40%
Combination Therapy
20%
Tumor Progression
20%
High Dose
20%
% Response
20%
Hypertension
20%
Biallelic
20%
Histologic
20%
Partial Response
20%
Human Cancer
20%
Crossover Design
20%
Neutralizing Antibodies
20%
Angiogenic Factors
20%
Antiangiogenic Agents
20%
Hypoxia-inducible Factor
20%
Randomized Placebo-controlled Trial
20%
Double-blind Trial
20%
3 to 5 Years
20%
Combination Strategy
20%
Time to Tumor Progression
20%
Medicine and Dentistry
Bevacizumab
100%
Kidney Cancer
100%
Cancer Cell
50%
Vasculotropin
50%
Tumor Progression
33%
Disease Exacerbation
33%
Proteinuria
33%
Clear Cell
33%
Toxicity
33%
Malignant Neoplasm
16%
Combination Therapy
16%
Kidney Function
16%
Drug Megadose
16%
Placebo
16%
Upregulation
16%
Neutralizing Antibody
16%
Hypoxia Inducible Factor
16%
Angiogenesis Inhibitor
16%
Thalidomide
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Kidney Cancer
100%
Malignant Neoplasm
66%
Vasculotropin
50%
Tumor Growth
33%
Disease Exacerbation
33%
Toxicity
33%
Proteinuria
33%
Placebo
16%
Combination Therapy
16%
Neutralizing Antibody
16%
Angiogenic Factor
16%
Angiogenesis Inhibitor
16%
Hypoxia Inducible Factor
16%
Thalidomide
16%
Neuroscience
Bevacizumab
100%
Vascular Endothelial Growth Factor
50%
Placebo
16%
Neutralizing Antibody
16%
Angiogenic Factor
16%
Angiogenesis Inhibitor
16%
Hypoxia-Inducible Factors
16%